IGF-1 LR3 Mechanism of Action — Research Reference

IGF-1 LR3 (Long R3 IGF-1) is an engineered analogue of insulin-like growth factor 1 with two structural modifications that produce a substantially longer half-life and IGFBP-resistant profile compared to native IGF-1.

Structural Modifications

1. Arginine substitution at position 3 (Glu³ → Arg³) — abolishes binding to insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6).
2. N-terminal 13-amino-acid extension — further reduces IGFBP affinity and contributes to clearance resistance.

The result is a circulating peptide that is essentially "free" — not buffered by binding proteins as native IGF-1 is — with a published half-life of approximately 20–30 hours versus minutes for free native IGF-1.

Receptor Target

IGF-1 LR3 binds the insulin-like growth factor 1 receptor (IGF-1R) with affinity comparable to native IGF-1. It also cross-reacts weakly with the insulin receptor and IGF-1R/IR hybrid receptors.

Signal Transduction

IGF-1R is a receptor tyrosine kinase. Ligand binding triggers:

1. IRS-1/2 → PI3K → Akt → mTORC1 — drives protein synthesis, cell growth, and glucose uptake.
2. Grb2 → SOS → Ras → MAPK/ERK — drives proliferative and differentiative responses.
3. mTORC2 → Akt phosphorylation feedback — stabilizes Akt signalling.

The PI3K-Akt-mTOR arm is the most-cited pathway in skeletal-muscle and tissue-growth research; the Ras-MAPK arm dominates in proliferation and oncology-context research.

Pharmacokinetic Consequence

Because LR3 evades the IGFBP buffering system, plasma free-IGF-1-equivalent activity sustains for hours rather than minutes. This produces continuous receptor engagement, in contrast to the pulsatile signal characteristic of endogenous IGF-1.

Receptor Internalization

Sustained ligand exposure produces measurable IGF-1R internalization and downregulation in cellular models — the published basis for cycled-administration protocols in IGF-1 LR3 research.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Tomas FM, Knowles SE, Owens PC, et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and Long R3-IGF-I. Biochem J. 1991;276(Pt 2):547–554.
2. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213–223.
3. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6(10):821–833.